Nkarta, Inc. (NKTX)
NASDAQ: NKTX · IEX Real-Time Price · USD
-0.09 (-1.42%)
Jun 13, 2024, 4:00 PM EDT - Market closed

Company Description

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.

The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.

It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors.

In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease.

It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Nkarta, Inc.
Nkarta logo
Country United States
Founded 2015
IPO Date Jul 10, 2020
Industry Biotechnology
Sector Healthcare
Employees 150
CEO Paul J. Hastings

Contact Details

1150 Veterans Boulevard
South San Francisco, California 94080
United States
Phone (925) 407-1049
Website nkartatx.com

Stock Details

Ticker Symbol NKTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001787400
CUSIP Number 65487U108
ISIN Number US65487U1088
Employer ID 47-4515206
SIC Code 2834

Key Executives

Name Position
Paul J. Hastings Chief Executive Officer, President and Director
Dr. Alicia J. Hager Chief Legal Officer and Corporate Secretary
Alyssa Levin C.A., CPA Chief Financial and Business Officer and Principal Accounting Officer
Dr. Ralph Brandenberger Ph.D. Chief Technical Officer
Dr. James Trager Ph.D. Chief Scientific Officer
Greg Mann Vice President of Public Affairs and Investor Relations
Dr. David R. Shook M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
Apr 25, 2024 ARS Filing
Apr 25, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2024 DEF 14A Other definitive proxy statements
Apr 15, 2024 PRE 14A Other preliminary proxy statements
Apr 5, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 29, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 29, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 28, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership